Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab

Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab

Given the increasing use of combination therapy with multiple monoclonal antibodies (mAbs), there is a clinical need for multiplexing assays. For the frequently co-administered anti-human epidermal growth factor receptor 2 (HER2) mAbs trastuzumab and pertuzumab, we developed a high-throughput and ro...

Full description

Bibliographic Details
Main Authors: Sandor Schokker, Fabrizia Fusetti, Francesco Bonardi, Remco J. Molenaar, Ron A.A. Mathôt, Hanneke W.M. van Laarhoven
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:mAbs
Subjects:
Trastuzumab
pertuzumab
mAbs
monoclonal antibodies
lc-MS
pharmacokinetics
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2020.1795492

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2020.1795492

Similar Items